Press releases
2024
18 Apr 2024, 07:00 | Regulatory
• Strong sales performance and solid momentum with the Phase 3 trial in anti-GBM disease
• Cash runway extended into 2026
• Evan Ballantyne joins Hansa Biopharma as Chief Financial Officer
• Cash runway extended into 2026
• Evan Ballantyne joins Hansa Biopharma as Chief Financial Officer
12 Apr 2024, 03:40 | Regulatory
2 Apr 2024, 07:00 | Regulatory
Company expects revenue of SEK 54m including product sales of SEK 48m - an increase of 10% versus the prior quarter and a 234% increase versus Q1 2023
Q1 2024 is the first time Hansa has delivered two consecutive quarters of strong revenue and growth
Q1 2024 is the first time Hansa has delivered two consecutive quarters of strong revenue and growth
21 Mar 2024, 07:00 | Regulatory
Company delivered significant progress across commercial and R&D priorities
22 Feb 2024, 15:00
2 Feb 2024, 07:00 | Regulatory
· Strong revenue generation in Q4 2023 including SEK 43m in Idefirix® product sales supported by growth in new markets such as U.K., Germany, and Spain
· Encouraging results from first-in-human trial of HNSA-5487
· Initiation of phase 1b trial of imlifidase as pre-treatment to Sarepta’s SRP-9001 in DMD
6 Jan 2024, 14:00 | Regulatory
· Strong revenue generation in Q4 2023, including SEK 43m in Idefirix[®] product sales supported by growth in new markets such as U.K., Germany, and Spain
· Encouraging first results from first-in-human trial of HNSA-5487, Hansa’s lead candidate from the NiceR program for repeat dosing
· Initiation of phase 1b trial of imlifidase as pre-treatment to Sarepta’s SR…
2023
14 Dec 2023, 20:00 | Regulatory
Statistically significant reduction in donor-specific antibodies (DSAs) observed among imlifidase patients within five days of treatment as compared to standard of care